Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer.

Surgery - 1 Dec 2010

Nehs Matthew A, Nagarkatti Sushruta, Nucera Carmelo, Hodin Richard A, Parangi Sareh

Abstract excerpt

BACKGROUND: B-Raf(V600E) is a frequent mutation in anaplastic thyroid cancers and is a novel therapeutic target. We hypothesized that PLX4720 (an inhibitor of B-Raf(V600E)) and thyroidectomy would extend survival and would decrease tumor burden in a mouse model. METHODS: Orthotopic anaplastic thy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Combined Modality Therapy
Share to Cost of Illness
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoadjuvant Therapy

Share to Sulfonamides

Share to Thyroid Carcinoma, Anaplastic

Share to Thyroid Neoplasms

Share to Thyroidectomy

Source

Open in PubMed Open full text

Identifiers

PMID: 21134546
DOI: 10.1016/j.surg.2010.09.001
PMCID: PMC3413092

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21134546-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer.PMID 21134546Read ↗

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.Semantic proximity Read ↗

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapiesSemantic proximity Read ↗

Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAFSemantic proximity Read ↗

p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.Semantic proximity Read ↗

ALK Inhibition Prolongs Survival in a Mouse Model of ALK-positive Anaplastic Thyroid CancerSemantic proximity Read ↗

Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cellsSemantic proximity Read ↗

Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid CancerSemantic proximity Read ↗

Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.Semantic proximity Read ↗

Dual targeting of PDPK1 and BRAF V600E is synthetically lethalSemantic proximity Read ↗

Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma.Semantic proximity Read ↗

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.Semantic proximity Read ↗

Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.